Last updated on June 2020

An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Connective Tissue Diseases | SYSTEMIC LUPUS ERYTHEMATOSUS | CONNECTIVE TISSUE DISEASE | Autoimmune disease | Dermatomyositis (Connective Tissue Disease)
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit

Inclusion Criteria:

  • Meets the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE and diagnosed 24 weeks before the screening visit
  • One of the following: antinuclear antibody (ANA) 1:80 or positive anti-double-stranded DNA (dsDNA) or positive anti-Smith (Sm)
  • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score 6 points and clinical SLEDAI-2K score 4 points

Exclusion Criteria:

  • Subjects with drug-induced SLE, certain other autoimmune diseases, and active, severe lupus nephritis
  • SLE overlap syndromes such as scleroderma and mixed connective tissue disease
  • Clinically significant abnormalities on chest x-ray or ECG
  • History of any significant drug allergy

Other protocol defined inclusion/exclusion criteria could apply

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.